Ayvakit (Avapritinib)

This is a medication used to treat certain types of stomach cancer (gastric cancer). It works by blocking the growth of cancer cells. It's a specific type of drug called a tyrosine kinase inhibitor.

Brand names:Ayvakit
Medication

What people taking Ayvakit (Avapritinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ayvakit (Avapritinib) for Systemic Mastocytosis?

NameHow it went

About Ayvakit (Avapritinib)

What It's For

Avapritinib, sold as Ayvakit, is a targeted oral medicine for two rare conditions driven by specific genetic changes. In the US it is approved for adults only. The first is gastrointestinal stromal tumor (GIST), a cancer that usually starts in the wall of the stomach or intestine. Avapritinib is used when GIST cannot be removed with surgery or has spread, and only when testing of the tumor finds a mutation in a gene called PDGFRA (in a region known as exon 18, most often the D842V change). This particular mutation makes GIST resistant to the kinase inhibitors usually used for it, which is why avapritinib fills an important gap. It is not a general treatment for other types of GIST. The second is systemic mastocytosis, a condition in which too many mast cells (a type of immune cell) build up in the bone marrow and other organs. Avapritinib is approved for advanced systemic mastocytosis, which includes aggressive systemic mastocytosis, systemic mastocytosis with an associated blood cancer, and mast cell leukemia. It is also approved for indolent systemic mastocytosis, the slower, more common form, where the goal is to ease symptoms such as flushing, itching, diarrhea, bone pain, fatigue and brain fog. For either form, it is not recommended when the platelet count is very low.

How It Works

Kinases are proteins that act as on-off switches for cell growth. In these conditions, a mutation leaves one of two kinase switches, KIT or PDGFRA, stuck in the on position. In GIST, a stuck PDGFRA switch drives tumor growth. In systemic mastocytosis, a KIT mutation called D816V, found in more than 90% of people in the clinical trials, keeps mast cells multiplying. Avapritinib is a kinase inhibitor designed to block these mutated forms of KIT and PDGFRA. Blocking the signal slows or stops the growth of the abnormal cells. In GIST this can shrink tumors; in mastocytosis it lowers the number of mast cells, which can ease the symptoms they cause. It controls the disease while it is taken rather than curing it.

Dosage & Administration

Avapritinib is a tablet taken by mouth once a day on an empty stomach, at least 1 hour before or 2 hours after a meal. The dose depends strongly on the condition, so a dose meant for one use should never be assumed for another. The usual starting dose is 300 mg for GIST and 200 mg for advanced systemic mastocytosis, while indolent systemic mastocytosis uses a much lower 25 mg dose. Doses are often reduced or paused to manage side effects, and lower starting doses are used for severe liver disease or when an interacting medicine cannot be avoided. If a dose is missed, it can be taken unless the next dose is due within 8 hours. If you vomit after taking a dose, do not take another; take the next one at the usual time.

Side Effects

Side effects are much more frequent at the higher doses used for GIST and advanced mastocytosis. In those groups, the most common are swelling (often around the eyes, face, ankles or legs), nausea, fatigue, diarrhea, vomiting, reduced appetite, watery eyes, abdominal pain, dizziness, rash and changes in hair color. Dose reductions are common and often make treatment easier to continue. At the 25 mg dose for indolent mastocytosis, side effects are usually mild, most often swelling around the eyes or legs, dizziness and flushing. Avapritinib can affect thinking. Memory problems, trouble concentrating and confusion occurred in about 4 in 10 people treated for GIST and nearly 3 in 10 with advanced mastocytosis, usually starting within the first few months; they were about as common as with placebo at the indolent dose. Family members often notice these changes first. Tell the care team about new or worsening memory problems or confusion, since a pause or lower dose usually helps, and do not drive or operate machinery while affected. Rarely, avapritinib causes bleeding inside the skull, which can be fatal. It was seen with the higher doses, not in the indolent mastocytosis trial. A sudden severe headache, vomiting, unusual drowsiness, confusion, vision changes, slurred speech or weakness or paralysis on one side are an emergency: call 911 or get emergency care right away. Avapritinib is stopped permanently if this happens. The skin can burn more easily in sunlight, so use sunscreen and protective clothing during treatment and for a week after stopping.

Interactions & Warnings

Avapritinib is broken down by a liver enzyme called CYP3A. Medicines or supplements that strongly or moderately block this enzyme can raise avapritinib levels and its side effects, and those that speed it up can make treatment less effective. Because many products affect CYP3A, check with the oncologist or pharmacist before starting anything new, including over-the-counter medicines and supplements. Blood thinners and a low platelet count add to the risk of brain bleeding, so the care team should know about them, along with any past brain bleed, aneurysm or recent stroke. Avapritinib can harm a developing baby. Women who could become pregnant, and men with partners who could, should use effective contraception during treatment and for 6 weeks after the last dose, and a suspected pregnancy should be reported to the care team. Avapritinib can raise levels of ethinyl estradiol, the estrogen in many birth control pills, so the type of contraception is worth discussing. Breastfeeding is not advised during treatment and for 2 weeks after the last dose. The higher doses may also reduce fertility in both women and men.

What to Expect

Avapritinib is generally taken for as long as it keeps working and side effects remain manageable. For GIST, scans are repeated to check whether tumors are shrinking or stable. In the main trial for PDGFRA exon 18 GIST, about 84% of people had substantial tumor shrinkage, and most responses were still ongoing when the results were reported, though this was a small study without a comparison group. In advanced mastocytosis, about 57% of people in the trials responded, typically within about 2 months, and responses often lasted for years. Platelet counts are checked before starting, every 2 weeks for the first 8 weeks, and then according to the results, because low platelets raise the bleeding risk. In indolent mastocytosis, avapritinib is added to existing symptom treatments such as antihistamines. In a placebo-controlled trial of people whose symptoms persisted despite at least two such treatments, symptom scores improved more over 24 weeks with avapritinib, and blood tryptase (a marker of mast cell burden) fell by half or more in just over half of those treated. Improvement is gradual and varies from person to person. Regular visits track side effects, blood counts and other lab results, and doses are adjusted along the way.

Questions to Ask Your Doctor

  1. 1.What did testing show about my mutation, and why is avapritinib a better fit than other options for me?
  2. 2.What dose am I starting on, and how will we decide whether to lower or pause it?
  3. 3.How will we measure whether it is working, and how soon should we know?
  4. 4.Which of my current medicines or supplements interact with avapritinib, and do I need a different form of birth control?
  5. 5.Do I have any risk factors for brain bleeding, and what memory or thinking changes should my family watch for?

Last reviewed • Oct 2026

Educational content, not medical advice.